Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. - Wikidata - awgldk - TriplyDB

Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.

Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.

http://www.wikidata.org/entity/Q34290067

about

Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs Alternatively spliced transcripts and novel pseudogenes of the Plasmodium falciparum resistance-associated locus pfcrt detected in East African malaria patients Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis.Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria.Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria.Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia.Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Incorporating Stage-Specific Drug Action into Pharmacological Modeling of Antimalarial Drug Treatment Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children.Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria.Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers.Teratogenicity of Artemether-Clindamycin Nanostructured Lipid Carriers in Rats.Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling.Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations.Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.Population pharmacokinetics of artemether, dihydroartemisinin and lumefantrine in Rwandese pregnant women treated for uncomplicated malaria

P2860

Q26783646-789FC99F-5156-446A-83F3-876D789BB1D5 Q26830528-F405AEFE-AD2A-4B62-A776-2A9A88E0BD34 Q27025529-3A31BD6E-3EDD-419A-82EA-839D8258D10F Q28649722-64E90BCD-9155-4803-B486-CB209BC35AFF Q30995133-A3021B2E-75F3-4780-995B-28E64243A5B6 Q33678483-08C9EB58-ADD1-4895-B11C-257830C16216 Q34953705-E92DF08E-A7C8-4DA1-BFBD-2D10F63C1E7F Q35191375-8015E27F-0026-46BB-9B5C-7B54C6EC72B6 Q35363704-0C3DD8B9-D3AA-435A-B7B1-05DBF335EF99 Q35607695-60A4D340-A311-4105-BE8F-807350DA2F3E Q35607781-35A5822A-C4CC-498F-8482-FE0A58876A49 Q35761064-884D7A06-9C68-43CA-85F0-48A91428D7CE Q36018444-D683FBCD-4668-4CF6-B436-806F96ED38FB Q36076111-C2ED9D4D-D6C0-4A4D-9255-0985E3B12BC9 Q36088256-6B8A1CBD-70D5-4770-B287-B56D25EE9D4A Q36364184-4AF5D58E-3EF3-4FEB-909A-C34A92B26679 Q36411652-552790A0-B275-4E02-BCB7-0B1FF9ECB353 Q36412071-70AF3A53-A812-4D33-9C62-59AFEC487D7B Q36584636-C2A50915-C897-4DA3-9490-9507752F07EB Q36684146-3D482498-E699-42A4-A05F-734FCA7DE87B Q36888028-C2F2479A-227B-40D0-B990-6EB1708BF423 Q36918510-804A6DF4-A3CC-4031-B5CA-D4C4B6B169A0 Q37038270-06DE4573-3E7A-4DD2-BD0F-564CBF30AE62 Q37279764-686205A8-8E09-4D68-B8BB-8E9BDEE3BBD7 Q38071558-94D9400C-DB76-4F32-B371-20F5FDCB1135 Q38852053-8139A5CB-B6B5-429B-8887-FEC0366AEE26 Q38865815-E99A6DC0-8961-4A0A-B372-974812598372 Q39698875-7B17E14A-8124-498F-8F62-ECF8A995B720 Q43924014-93C9BDAC-3017-4E63-B830-FA185AF640C0 Q46405195-15A17B8C-75F9-4682-BD61-121753295768 Q55449589-14620747-BBAC-4432-93FD-D692A18244B3 Q56354961-11F22E6E-E842-4AFF-8F68-DD389BB72FF0

P2860

Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.

http://www.wikidata.org/entity/Q34290067

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Population pharmacokinetics an ...... alciparum malaria in Tanzania.

@ast

Population pharmacokinetics an ...... alciparum malaria in Tanzania.

@en

Population pharmacokinetics an ...... alciparum malaria in Tanzania.

@nl

type

label

Population pharmacokinetics an ...... alciparum malaria in Tanzania.

@ast

Population pharmacokinetics an ...... alciparum malaria in Tanzania.

@en

Population pharmacokinetics an ...... alciparum malaria in Tanzania.

@nl

prefLabel

Population pharmacokinetics an ...... alciparum malaria in Tanzania.

@ast

Population pharmacokinetics an ...... alciparum malaria in Tanzania.

@en

Population pharmacokinetics an ...... alciparum malaria in Tanzania.

@nl

P1433

Q34290067-FB67D0DF-8FB3-4346-9659-BAF9D8FADC34

P1476

Q34290067-72C70A5B-E629-4DA9-9ECF-EEF669EA2876

P2093

Q34290067-0870737B-61E2-4CBA-A44C-A3989FAA92C8

Q34290067-2B4A975A-7EC6-490F-B089-8DDD373AEF90

Q34290067-54EC22AE-2D59-4E91-8DA3-68744ADF2149

Q34290067-5CBBE2BB-5F7C-48AE-8E5A-494010F2756C

Q34290067-905B08C5-6F2F-429E-9CDB-D9C45788BB95

Q34290067-9309DD59-A509-41C2-9CCC-0E76678B8C49

Q34290067-BCF8B114-B7D3-4F42-9EF2-5900A5554BFD

Q34290067-C0548003-11DB-4F2D-814B-3C2DB7240510

Q34290067-E911CBCC-96B0-40E7-B0FC-51024AF3198A

P2860

Q34290067-02202D50-1576-45EA-904A-DC11459377CA

Q34290067-04899807-DB67-4484-BCF8-86971A6CFDB7

Q34290067-06A41188-D6D3-49EA-B634-8417A49B6A3B

Q34290067-158457E8-C517-4A5F-9122-1F85084C842E

Q34290067-1AFCAFF6-B167-4358-9CCF-F90529377E83

Q34290067-1CA93AF3-CACF-43C2-A8ED-B5D9A686EC00

Q34290067-1DDB94D7-6EC6-4433-8B20-421D03F8BC01

Q34290067-23280149-930E-46C0-A6C1-CA65EA45B105

Q34290067-33708860-0863-40FE-AC65-BAC217A781F2

Q34290067-36D4962C-563A-488C-9593-93A787A9F09A

P304

Q34290067-D2D839CC-BBFA-4C33-9672-2E08CA57FFA6

P31

Q34290067-45F6E4BB-CB74-4B78-9785-69F0835515FB

P356

Q34290067-58BE44FF-B431-475A-8DF3-12D791D9DCB7

P407

Q34290067-11D15BF1-F2CD-4F68-896A-C7D5963AC119

P433

Q34290067-AE1CC8D6-8AFE-47EB-A786-A028101D37E5

P478

Q34290067-48DDD506-DCF3-4802-9D58-1E895673A55A

P50

Q34290067-487F1BF1-A6B6-44D4-A82F-501E80970E11

Q34290067-7ACE535F-07B0-4505-98F1-CE108528626C

P577

Q34290067-73D1D4B5-292C-460C-8933-942ED45A909B

P5875

Q34290067-35A5AE72-71FC-4D6C-AD91-1CDA452FEE0B

P698

Q34290067-B8C65912-AEAC-4004-AD4A-6A639D2ADE78

P921

Q34290067-030C477C-A3C8-4544-A850-4EE03A378424

Q34290067-448AE631-FDFF-4FCD-8789-B450E5737BD0

Q34290067-C439994D-734D-468D-865C-2DFC6160BA3D

P932

Q34290067-7E6E04F0-ADB0-4D37-BBBE-483B1561A7DB

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Population pharmacokinetics an ...... alciparum malaria in Tanzania.

@en

P2093

Andreas Mårtensson

http://www.w3.org/2001/XMLSchema#string

Anna Annerberg

http://www.w3.org/2001/XMLSchema#string

Billy Ngasala

http://www.w3.org/2001/XMLSchema#string

Michael Ashton

http://www.w3.org/2001/XMLSchema#string

Niklas Lindegårdh

http://www.w3.org/2001/XMLSchema#string

Pedro Gil

http://www.w3.org/2001/XMLSchema#string

Sabina Dahlström

http://www.w3.org/2001/XMLSchema#string

Sofia Friberg Hietala

http://www.w3.org/2001/XMLSchema#string

Zul Premji

http://www.w3.org/2001/XMLSchema#string

P2860

Assessment of the pharmacodynamic properties of antimalarial drugs in vivo

Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2

Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria.

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.

Febrile temperatures induce cytoadherence of ring-stage Plasmodium falciparum-infected erythrocytes.

Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.

Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda.

Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

P304

4780-4788

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00252-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Anders Björkman

P577

2010-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45659989

http://www.w3.org/2001/XMLSchema#string

P698

20713675

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum

P932

2976134

http://www.w3.org/2001/XMLSchema#string